DSP Group Inc. (NASDAQ:DSPG) shares moved up 2.96% in last trading session and ended the day at $10.10. DSPG Gross Margin is 40.30% and its has a return on assets of 2.60%. DSP Group Inc. (NASDAQ:DSPG) quarterly performance is 15.30%.
On 28 October, DSP Group Inc. (NASDAQ:DSPG) announced its results for the third quarter ended September 30, 2015. Revenues for the third quarter of 2015 were $35.2 million, a decrease of 4% from revenues of $36.7 million for the third quarter of 2014. Net income for the third quarter of 2015 was $167,000, as compared to net income of $773,000 for the third quarter of 2014.
Hannon Armstrong Sustnbl Infrstr Cap Inc (NYSE:HASI) ended the last trading day at $17.69. Company weekly volatility is calculated as 2.93% and price to cash ratio as 30.59. Hannon Armstrong Sustnbl Infrstr Cap Inc (NYSE:HASI) showed a weekly performance of -1.78%.
On 4 November, Hannon Armstrong Sustnbl Infrstr Cap Inc (NYSE:HASI) reported Core Earnings, a non-GAAP financial measure, for the quarter ended September 30, 2015, of $8.5 million or $0.26 per share, an increase of 18% over the $0.22 per share in the same quarter last year. For the nine months ended September 30, 2015, Core Earnings were $24.0 million or $0.79 per share, as compared to $13.2 million or $0.64 per share in the same period last year.
PDL BioPharma, Inc. (NASDAQ:PDLI) caters to the Healthcare space. It has a net profit margin of 56.20% and weekly performance is -10.92%. On the last day of trading company shares ended up at $4.08. PDL BioPharma, Inc. (NASDAQ:PDLI) distance from 50-day simple moving average (SMA50) is 4.42%.
PDL BioPharma, Inc. (NASDAQ:PDLI) issued financial results for the third quarter on Wednesday, November 4, 2015 and has subsequently received numerous inquiries on its reported royalties from royalty rights it acquired from Depomed, Inc. (Depomed). Specifically, the nature of the questions was about royalties for Glumetza® which is currently marketed and sold by Valeant Pharmaceuticals International, Inc. (Valeant).
Theravance Biopharma, Inc. (NASDAQ:TBPH) shares moved up 1.51% in last trading session and ended the day at $17.50. TBPH Gross Margin is 87.30% and its has a return on assets of -62.60%. Theravance Biopharma, Inc. (NASDAQ:TBPH) quarterly performance is 41.82%.
On 2 November, Theravance Biopharma, Inc. (NASDAQ:TBPH) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of TD-1473, a novel, potent, and orally administered GI-targeted pan-Janus kinase (JAK) inhibitor. The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal disorders. Pending FDA’s acceptance of the filing, Theravance Biopharma will initiate a Phase 1 study investigating the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the compound in healthy subjects. The Company expects to initiate the Phase 1 trial by early 2016.
Covenant Transportation Group, Inc. (NASDAQ:CVTI) caters to the Services space. It has a net profit margin of 5.00% and weekly performance is 13.37%. On the last day of trading company shares ended up at $21.88. Covenant Transportation Group, Inc. (NASDAQ:CVTI) distance from 50-day simple moving average (SMA50) is -1.70%.
Covenant Transportation Group, Inc. (NASDAQ:CVTI) was upgraded by Zacks from a “sell” rating to a “hold” rating in a note issued to investors on Sunday,AnalystRatings.Net reports.